Drug Trial Radar · NCT00689104
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,336
Actual
Start
Apr 28, 2008
Primary completion
Mar 24, 2009
Study completion Mar 24, 2009
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
Conditions
- Urinary Bladder, Overactive
Interventions
MirabegronDrug
Tablets
TolterodineDrug
Capsules
Placebo to MirabegronDrug
Matching mirabegron placebo tablets.
Placebo to TolterodineDrug
Matching tolterodine placebo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and Week 12 (final visit)
- Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and Week 12
Locations
218 sites in 30 countries. Site status is shown where the registry gives one.
Site not named
Auchenflower, Australia
Site not named
Clayton, Australia
Site not named
Kogarah, Australia
Site not named
Randwick, Australia
Site not named
Woolloongabba, Australia
Site not named
Graz, Austria
Site not named
Innsbruck, Austria
Site not named
Linz, Austria
Site not named
Minsk, Belarus
Site not named
Minsk, Belarus
Site not named
Minsk, Belarus
Site not named
Antwerp, Belgium
Site not named
Antwerp, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Leper, Belgium
Site not named
Leuven, Belgium
Site not named
Liège, Belgium
Site not named
Sint-Truiden, Belgium
Site not named
Pleven, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Brno, Czechia
Site not named
Mělník, Czechia
Site not named
Olomouc, Czechia
Site not named
Ostrava-Poruba, Czechia
Site not named
Pilsen, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Štětí, Czechia
Site not named
Ústí nad Labem, Czechia
Site not named
Aalborg, Denmark
Site not named
Aarhus, Denmark
Site not named
Glostrup Municipality, Denmark
Site not named
Roskilde, Denmark
Site not named
Helsinki, Finland
Showing 40 of 218 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.